Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG

Fruquintinib

Fruquintinib: 5mg qd, po, 2 weeks on/1 week off, q3w, or 3mg qd, po, q3w.

DRUG

Sintilimab

Sintilimab: 200mg, iv, d1, q3w.

DRUG

Chidamide

Chidamide: 30mg/m2, po, biw.

Trial Locations (1)

RECRUITING

China PLAGH, Beijing

All Listed Sponsors

lead

Dai, Guanghai

OTHER